

Edgar Filing: ENZON INC - Form 8-K

ENZON INC  
Form 8-K  
November 22, 2002

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 22, 2002

ENZON, INC  
(Exact name of registrant as specified in its charter)

|  |  |  |
|--|--|--|
| DELAWARE<br>(State or Other<br>Jurisdiction of<br>Incorporation) | 0-12957<br>(Commission<br>File Number) | 22-2372868<br>(IRS Employer<br>Identification No.) |
|--|--|--|

685 Route 202/206, Bridgewater, New Jersey 08807  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (732) 980-4500

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On November 22, 2002, Enzon, Inc. announced the completion of its acquisition of the North American rights to ABELCET(R) (Amphotericin B Lipid Complex Injection) from Elan Corporation, plc. A copy of the press release dated November 22, 2002 announcing the completion of the transaction is attached hereto as Exhibit 99.1. Such Exhibit is incorporated by reference into this Item 5 and the foregoing statement is qualified in its entirety by reference to such Exhibit.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

- (a) Not applicable.
- (b) Not applicable.
- (c) Exhibits.

| Exhibit Number<br>----- | Description<br>-----                         |
|-------------------------|--|
| 99.1 -                  | Press Release, dated as of November 22, 2002 |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZON, INC.

Date: November 22, 2002

By: \_\_\_\_\_

Edgar Filing: ENZON INC - Form 8-K

Kenneth J. Zuerblis  
Vice President, Finance and  
Chief Financial Officer